GLP1R and type 2 diabetes mellitus: The remaining 10 criteria are novel and address the treatment of type 2 diabetes mellitus, including insulin (alone or in combination with liraglutide), glargine insulin, GLP-1, IDPP-4, and ISGLT-2 inhibitors.